Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
A landmark clinical trial, supported by the National Institutes of Health (NIH), has delivered pivotal findings indicating that weekly injectable extended-release buprenorphine offers superior outcomes for the treatment of opioid use disorder (OUD) during pregnancy compared to the current standard of daily sublingual buprenorphine. Published in the prestigious JAMA Internal Medicine on Monday, March 16, 2026, the study revealed significantly higher rates of illicit opioid abstinence among pregnant individuals receiving the extended-release formulation, alongside a reduced incidence of serious maternal adverse events. This groundbreaking research, part of the NIH Helping to End Addiction Long-term (HEAL) Initiative, marks a crucial advancement in addressing the complex challenges of OUD in one of the most vulnerable populations.
The Pervasive Challenge of Opioid Use Disorder in Pregnancy
The United States has been grappling with a devastating opioid crisis for over two decades, impacting millions and claiming hundreds of thousands of lives. Within this public health emergency, pregnant individuals with OUD face unique and profound challenges. Untreated or poorly managed OUD during pregnancy carries severe risks, including increased maternal mortality due to overdose, higher rates of obstetric complications such as preterm labor, placental abruption, and fetal growth restriction. Crucially, it also poses a significant threat to the newborn, with the potential development of neonatal opioid withdrawal syndrome (NOWS), a constellation of symptoms requiring specialized medical care post-birth.
Statistics underscore the gravity of the situation. The prevalence of OUD among pregnant individuals has been on a concerning upward trajectory, with estimates suggesting that hundreds of thousands of pregnancies are affected annually. The incidence of NOWS has similarly surged, placing immense strain on neonatal intensive care units and healthcare resources. Beyond the immediate health risks, OUD during pregnancy often correlates with socioeconomic instability, increased involvement with child protective services, and pervasive stigma, creating barriers to effective treatment and support. The societal costs, encompassing healthcare expenditures for mothers and infants, long-term developmental support for children, and lost productivity, are staggering, reaching billions of dollars annually. Addressing OUD in this demographic is not merely a clinical imperative but a comprehensive public health and social justice issue.
Evolution of Treatment: From Daily Dosing to Extended-Release Innovations
For decades, medication-assisted treatment (MAT) has been recognized as the gold standard for OUD, significantly improving patient outcomes, reducing illicit drug use, and decreasing mortality rates. Buprenorphine, often combined with naloxone in its sublingual form, has been a cornerstone of MAT, particularly favored during pregnancy due to its safety profile and established efficacy in mitigating withdrawal symptoms and cravings. Daily sublingual buprenorphine (SL-BUP) works by partially activating opioid receptors, thereby reducing withdrawal and cravings without producing the full euphoric effects of other opioids, while naloxone acts as an abuse deterrent.
However, despite its effectiveness, SL-BUP presents several practical disadvantages, especially for pregnant patients who often navigate complex life circumstances. The requirement for daily dosing can lead to challenges with adherence, particularly when coupled with other demands of pregnancy, childcare, and potential socioeconomic stressors. Missed doses can result in breakthrough cravings and withdrawal symptoms, increasing the risk of relapse to illicit opioid use. Furthermore, daily dosing can lead to "peak-trough effects," where blood levels of the medication fluctuate throughout the day, potentially leaving individuals vulnerable to cravings and discomfort during trough periods. The daily administration also carries a higher risk of diversion or misuse of the medication itself, although the naloxone component in combination formulations helps mitigate this. These limitations have long fueled the search for alternative formulations that could offer improved adherence, more stable medication levels, and reduced opportunities for misuse.
The NIH HEAL Initiative: Accelerating Solutions
Recognizing the urgent need for innovative solutions to combat the opioid crisis, the NIH launched the Helping to End Addiction Long-term (HEAL) Initiative in 2018. This ambitious, trans-NIH effort brings together researchers from various disciplines to develop and implement new strategies for preventing and treating OUD and managing pain. The HEAL Initiative’s comprehensive approach spans basic science, clinical research, and implementation science, aiming to accelerate the development of scientific solutions into clinical practice.
The present study on extended-release buprenorphine for pregnant individuals is a direct outcome of the HEAL Initiative’s commitment to addressing critical gaps in OUD treatment, particularly for vulnerable populations. By funding rigorous clinical trials through mechanisms like the NIDA Clinical Trials Network, HEAL aims to generate evidence that can rapidly translate into improved patient care and public health outcomes. The initiative’s focus on innovative therapies, including longer-acting formulations of MAT, aligns perfectly with the goals of this research to enhance treatment efficacy and adherence.
Designing a Landmark Randomized Controlled Trial
The clinical trial, supported by NIDA’s Clinical Trials Network, was meticulously designed as a multicenter, randomized study – the gold standard for evaluating treatment efficacy. A total of 140 pregnant adults diagnosed with OUD were recruited across various sites. Participants were randomly assigned to one of two treatment arms:
- Weekly Injectable Extended-Release Buprenorphine (ER-BUP): Administered subcutaneously (under the skin) once a week, providing a continuous, stable release of the medication. Participants in this arm also had the option to transition to a monthly formulation postpartum if they were not breastfeeding, further reducing the frequency of administration.
- Daily Sublingual Buprenorphine (SL-BUP): The standard of care, administered daily under the tongue, with or without naloxone as clinically indicated.
The primary objective of the trial was to compare the rates of illicit opioid abstinence between the two groups during pregnancy, as objectively measured by regular urine drug screens. Secondary outcomes included rates of maternal adverse events (both serious and non-serious) and neonatal opioid withdrawal syndrome (NOWS) outcomes for the newborns. The study design carefully monitored both maternal and fetal health parameters throughout pregnancy and continued follow-up for participants postpartum, providing a comprehensive assessment of safety and efficacy across different stages. This rigorous methodology ensured that the findings would be robust and clinically actionable, providing a strong evidence base for potential changes in treatment guidelines.
Key Findings: A New Standard of Care Emerges
The results of the trial were compelling and transformative. During the pregnancy phase, individuals randomized to receive weekly extended-release buprenorphine demonstrated significantly higher rates of illicit opioid abstinence compared to those receiving daily sublingual buprenorphine. This primary finding directly addresses one of the major challenges in OUD treatment during pregnancy: maintaining consistent abstinence from illicit substances to protect both mother and baby. The objective measure of urine drug screens provided clear, undeniable evidence of this superior efficacy.
Beyond abstinence rates, the study also revealed critical safety data. Serious maternal adverse events were notably less common in the extended-release buprenorphine group throughout the duration of the trial. While the percentage of participants experiencing non-serious maternal adverse events did not differ significantly between the two treatment arms, these events were more frequently rated as medication-related in the extended-release group during pregnancy, likely attributable to injection site reactions or initial adjustment to the new formulation. Crucially, in terms of neonatal outcomes, there was no significant difference in NOWS severity or incidence between the treatment groups. This indicates that while ER-BUP offered superior maternal outcomes, it did not negatively impact the infant’s experience of withdrawal compared to SL-BUP, reinforcing its safety profile. Postpartum, the rates of illicit opioid abstinence remained non-inferior for those who had received extended-release buprenorphine, particularly for those who transitioned to the monthly formulation, highlighting the sustained benefit of longer-acting treatments.
Expert Perspectives and Affirmations
The release of these findings has been met with significant enthusiasm from leading experts in addiction medicine and maternal health. Dr. Nora D. Volkow, director of NIH’s National Institute on Drug Abuse (NIDA), underscored the profound clinical significance of the trial. "These findings are clinically valuable for they show us that this injectable extended-release buprenorphine formulation is safe to use in pregnancy and results in better opioid abstinence outcomes compared to sublingual buprenorphine," stated Dr. Volkow. She further emphasized the timely relevance of this breakthrough, stating, "This is especially relevant in the context of the ongoing opioid overdose crisis and public health emergency." Her comments highlight NIDA’s commitment to translating research into practice to combat the devastating impact of opioids.
Dr. John Winhusen, Ph.D., professor of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine and the principal investigator and lead author of the study, expressed his excitement about the immediate clinical applicability of the results. "We knew that injectable extended-release buprenorphine leads to superior rates of illicit opioid abstinence in non-pregnant adults, but there had been no completed randomized clinical trial testing its use during pregnancy," Dr. Winhusen noted. "It is exciting to share the results of this trial, which have immediate clinical application: this longer-acting medication can safely and more effectively support treatment and recovery in pregnant patients." His statement underscores the significant void this research fills, providing robust evidence for a treatment option that promises to revolutionize care for this specific population. The medical community is expected to widely welcome these results, as they offer a clear, evidence-based pathway to improve patient care and potentially reduce the burden of OUD during pregnancy.
Implications for Clinical Practice and Policy
The findings from this NIH-supported trial are poised to significantly reshape the landscape of OUD treatment during pregnancy. Clinically, the superior abstinence rates and reduced serious adverse events associated with weekly extended-release buprenorphine strongly suggest it should be considered as a preferred treatment option. This could lead to updates in national and international clinical guidelines for managing OUD in pregnant individuals, potentially establishing ER-BUP as a new standard of care. For healthcare providers, it offers a powerful new tool that addresses many of the logistical and adherence challenges associated with daily sublingual formulations.
For patients, the implications are profound. A weekly or monthly injection regimen significantly reduces the burden of daily medication management, offering greater convenience, privacy, and potentially reducing the stigma associated with daily clinic visits or medication pickups. Improved adherence fostered by the longer-acting formulation can lead to more stable recovery, better maternal health outcomes, and a reduced likelihood of relapse, ultimately contributing to healthier pregnancies and improved maternal-infant bonding. The potential for reduced maternal adverse events further enhances patient safety and well-being.
From a policy perspective, these results will likely prompt discussions regarding insurance coverage and accessibility of extended-release buprenorphine for pregnant individuals. Ensuring that this effective treatment is readily available and affordable will be crucial for widespread implementation. Furthermore, there may be a need for increased training and education for healthcare providers, particularly obstetricians, family medicine physicians, and addiction specialists, on the administration and management of injectable buprenorphine in this population. The long-term societal benefits could include a reduction in healthcare costs associated with untreated OUD and NOWS, and improved public health outcomes for families affected by the opioid crisis.
Addressing Neonatal Opioid Withdrawal Syndrome (NOWS)
While the study found no significant difference in NOWS outcomes between the extended-release and sublingual buprenorphine groups, this is still a positive and reassuring finding. It confirms that the new formulation does not worsen NOWS, a critical consideration when introducing new treatments for pregnant individuals. Any effective treatment for OUD during pregnancy is paramount in mitigating the severity and incidence of NOWS compared to untreated OUD. NOWS remains a significant challenge, requiring specialized care, often in neonatal intensive care units, and can lead to prolonged hospital stays for infants. Continued research into strategies to further reduce NOWS severity, irrespective of buprenorphine formulation, remains an important area of focus. However, by ensuring sustained maternal abstinence and improving overall maternal health, the extended-release formulation indirectly contributes to a healthier prenatal environment for the infant, which is beneficial for NOWS prevention and management.
Future Directions and Continued Research
The success of this trial opens several avenues for future research and implementation efforts. Real-world implementation studies will be essential to understand the practicalities of integrating weekly injectable buprenorphine into diverse clinical settings, including rural and underserved areas. Research focusing on long-term follow-up of children born to mothers treated with extended-release buprenorphine will provide invaluable data on developmental trajectories and long-term health outcomes. Further investigation into patient preferences, cost-effectiveness analyses, and strategies to overcome potential barriers to access will also be crucial for maximizing the impact of these findings. This trial represents a significant step forward, but the journey toward fully eradicating the harms of OUD during pregnancy continues, driven by scientific innovation and compassionate care.
If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. To learn how to get support for mental health, drug or alcohol conditions, visit FindSupport.gov. If you are ready to locate a treatment facility or provider, you can go directly to FindTreatment.gov or call 800-662-HELP (4357).
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®
Reference
TJ Winhusen, et al. Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2026.0057
Related posts:
